Warfarin Dose Adjustment for INR 1.78
Increase your weekly warfarin dose by 10-15% (approximately 3-5 mg per week, bringing your total weekly dose to 35-37 mg) and recheck INR in 1-2 weeks.
Rationale for Dose Adjustment
Your current INR of 1.78 is subtherapeutic for the target range of 2.0-3.0. This places you at increased risk of thromboembolic events, which directly impacts morbidity and mortality outcomes 1. The evidence clearly demonstrates that INR values below 2.0 are associated with significantly greater risk of stroke and systemic thromboembolism 1.
Specific Dosing Strategy
For your situation with a weekly dose of 32 mg:
- Current daily average: ~4.6 mg/day
- Recommended adjustment: Increase total weekly dose by 10-15%
- New weekly dose: 35-37 mg (approximately 5 mg/day)
- Recheck timing: INR in 7-14 days 2
The FDA labeling supports flexible dosing adjustments based on INR response, noting that most patients are maintained on 2-10 mg daily 2. Research demonstrates that dose adjustments should typically alter the total weekly dose by 5-20% 3.
Why Not Just Continue Current Dose?
While recent research suggests that "watchful waiting" (maintaining the same dose) versus dose changes for slightly out-of-range INRs shows minimal difference 4, 5, this applies primarily to INRs that are minimally outside range (1.5-1.99 or 3.01-3.49). Your INR of 1.78 sits in the lower portion of this range and represents inadequate anticoagulation that warrants intervention to prevent thrombotic complications.
Important Monitoring Considerations
- Frequency: After dose adjustment, INR should be monitored within 1-2 weeks 2
- Stability: Once therapeutic range is achieved consistently, monitoring intervals can gradually extend to every 4-6 weeks 3
- Time in therapeutic range (TTR): Aim for >65% of INR values within 2.0-3.0 for optimal outcomes 1
Critical Safety Points
- The risk of thromboembolism increases substantially when INR remains <2.0 1
- Avoid large dose changes that could overshoot and cause excessive anticoagulation
- Consider factors that may be affecting your INR: medication changes, dietary vitamin K intake, illness, or adherence issues 2
- If you have genetic variations in CYP2C9 or VKORC1, you may require lower doses overall, but this doesn't change the need to adjust upward from your current subtherapeutic level 2
The goal is to achieve an INR of 2.5 (within the 2.0-3.0 range) to maximize protection against thromboembolism while minimizing bleeding risk 1, 2.